Prescription Drug Price Transparency
Related Sites
Prescription Drug Price Transparency Frequently Asked Questions
Registration and Reporting System User Guide (PDF)
What is Minnesota’s Prescription Drug Price Transparency Act?
The Prescription Drug Price Transparency Act (SF1098) is legislation that aims to increase transparency into prescription drug prices by requiring drug manufactures that set high or quickly increasing prices to report to price justification and other information to the Minnesota Department of Health (MDH). It was signed into law on May 15, 2020, creating Section 62J.84 of the Minnesota Statutes and was amended by Minnesota Laws, 2021, Regular Session, Chapter 30 – HF 2128 – Article 3, Sec. 5 - 9 on May 25, 2021.
Where can I find guidelines for reporting?
MDH expects to issue guidance on how to comply with the act by early summer 2021. We will share information related to the act’s implementation and opportunities for public feedback on this page, through GovDelivery bulletins, and via State Register announcements. At a June 10, 2021 meeting, MDH presented content from the draft Form and Manner document, which the agency expects to finalize in July, 2021.
Where can I sign up for more information?
To receive announcements on implementation of the act, please subscribe to Prescription Drug Price Transparency updates.
Why is Minnesota pursuing this work when other states are already requiring and posting this type of reporting?
This is a legislative requirement that grew out of bi-partisan deliberations in the Minnesota Legislature to better understand prescription drug pricing issues in Minnesota in order to more effectively design possible future prescription drug policies. However, Minnesota is in close contact with other states to learn from their efforts and identify any available information that is not being collected in Minnesota but could be of use to the stakeholders in the state. There is variation in the drugs reported, data elements included in a report, and timeline for reporting and public disclosure of reported information across states.
As Minnesota implements the act’s requirement, will it consider input from stakeholders, including pharmaceutical manufacturers?
Yes, Minnesota welcomes feedback from stakeholders, including the pharmaceutical industry, on implementing the act. Interested parties and individuals may reach out to staff via email (health.Rx@state.mn.us); MDH will also make available more formal opportunities to provide feedback on draft guidelines. These opportunities will be announced via GovDelivery bulletins and on the Announcements page.
When will the state report on findings from this price transparency initiative?
Current law requires manufacturers to report data to MDH beginning in January 2022 within 60 days following a price change or price for new drugs that meets the requirements in Section 62J.84 in subdivisions 3 to 5, as amended by Minnesota Laws, 2021, Regular Session, Chapter 30 – HF 2128 – Article 3, Sec. 5 - 9. MDH will subsequently post these data to its website. MDH is required to issue an annual report to the Minnesota legislature by May 15, 2022, and January 15 of every year thereafter. Subscribers to announcements about the act will receive periodic updates about new information posted to the website.